Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Bonum Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$250.0 million","newsHeadline":"Good Therapeutics Announces Acquisition of Conditionally Active PD-1-Regulated IL-2 Program by Roche","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Bonum Therapeutics","sponsor":"Roche Venture Fund","pharmaFlowCategory":"D","amount":"$93.0 million","upfrontCash":"Undisclosed","newsHeadline":"Bonum Therapeutics Announces a $93M Series A Financing to Advance a Novel and Validated Class of Conditionally Active Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform"}]

    Find Clinical Drug Pipeline Developments & Deals by Bonum Therapeutics

    Menu

    Bonum Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Bonum Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Bonum Therapeutics Announces a $93M Series A Financing to Advance a Novel and Validated Class of Conditionally Active Therapies

              Details:

              The Series A financing will allow Bonum to apply the technology to regulated cytokines, including IL-12, IFN-alpha, and TGF-beta for immuno-oncology applications.

              Lead Product(s): PDL1 Dependent INF-alpha Therapy

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Large molecule

              Partner/Sponsor/Collaborator: Roche Venture Fund

              Deal Size: $93.0 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing November 15, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Bonum Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Good Therapeutics Announces Acquisition of Conditionally Active PD-1-Regulated IL-2 Program by Roche

              Details:

              The acquisition will give Roche rights to Good Therapeutics’ innovative, conditionally active, PD-1-regulated IL-2 program and an exclusive right to the platform technology for the development of PD-1-regulated IL-2 receptor agonist therapeutics.

              Lead Product(s): PD-1-targeted IL-2 Therapy

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Large molecule

              Partner/Sponsor/Collaborator: F. Hoffmann-La Roche

              Deal Size: Undisclosed Upfront Cash: $250.0 million

              Deal Type: Acquisition September 07, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Inke S.A: APIs manufacturing plant.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY